Transforming growth factor-β1 and prostate cancer

Scandinavian Journal of Urology and Nephrology

Volumn 34, Issue 2, 2000, Pages 85-94

  Wikstrom P ^a   Bergh, A ^a   Damber, J E ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Angiogenesis; Immunosuppression; Metastasis; Regulation of prostate growth; TGF 1

Indexed keywords

ANDROGEN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; CANCER GROWTH; CASTRATION; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE RELEASE; EPITHELIUM CELL; GENE OVEREXPRESSION; HORMONE DEPENDENCE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SEMINAL PLASMA;

DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 0034519224     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655900750016689     Document Type: Review

References (104)

1. Geographical and temporal patterns of incidence and mortality from prostate cancer
2. Cancer in the European community and its member states
3. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate
4. Treatment of advanced prostatic cancer
5. Prostate epithelial differentiation is dictated by its surrounding stroma
6. Role of androgen in prostate growth and regression: Stromal-epithelial interaction
7. Antagonistic effect of androgen on prostatic cell death
8. Growth factor involvement in progression of prostate cancer
9. Peptide growth factors in prostate cancer: A focus on transforming growth factor-β1
10. Transdifferentiation of NRP-152 prostatic basal epithelial cells toward a luminal phenotype: Regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-β
11. Transforming growth factor-β in benign and malignant prostate
12. Transforming growth factor β1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma
13. Expression of transforming growth factor-beta I in prostate cancer
14. Transforming growth factor beta1 as a biomarker for prostate cancer
15. Association of transforming growth factor beta1 with prostate cancer: An immunohistochemical study
16. Transforming growth factorbeta1 overproduction in prostate cancer: Effects of growth in vivo and in vitro
17. Down-regulation of protein and mRNA expression for transforming growth factor-β (TGF-β1) type I and type II receptors in human prostate cancer
18. Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissue
19. Reduced levels of transforming growth factor β receptor type II in human prostate cancer: An immunohistochemical study
20. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer
21. The TGF-beta superfamily: New members, new receptors, and new genetic tests of function in different organisms
22. The transforming growth factor-β family
23. Transforming growth factor-β signaling in epithelial cells
24. Mesenchymal-epithelial interactions and transforming growth factor-β during mouse prostate morphogenesis
25. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization
26. Latent high molecular weight complex of transforming growth factor β1: Purification from human platelets and structural characterization
27. Latent transforming growth factor-β: Structural features and mechanisms of activation
28. Mechanisms of TGF-β-induced cell cycle arrest
29. Effect of transforming growth factor-beta1 on proliferation and death of rat prostatic cells
30. Induction of apoptosis by transforming growth factor β1 in glioma and trigeminal neurinoma cells
31. Apoptosis is induced by transforming growth factor-beta I within 5 hours in regressing liver without significant fragmentation of the DNA
32. Transforming growth factor-beta 1 (TGF beta 1) enhances apoptosis in human papillomavirus type 16-immortalized human ectocervical epithelial cells
33. Coordinated regulation of apoptosis and cell proliferation by transforming growth factor β in cultured murine epithelial cells
34. Effects of transforming growth factor β1 on growth and apoptosis of human acute myelogenous leukemia cells
35. Transforming growth factor β1 induces apoptotic cell death in cultured human gastric carcinoma cells
36. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity
37. Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of meth sarcoma cells
38. Receptors for transforming growth factor-β
39. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells
40. Betaglycan presents ligand to the TGFβ signaling receptor
41. Expression cloning and characterization of the TGF-β type III receptor
42. Mechanism of activation of the TGF-β receptor
43. TGF-β signalling from cell to nucleus through SMAD proteins
44. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells
45. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells
46. Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells
47. Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities
48. Expression of TGF-β1 in rat ventral prostate and Dunning R3327 PAP prostate tumour after castration and estrogen treatment
49. Growth factors in expressed prostatic fluid from men with prostate cancer, BPH, and clinically normal prostates
50. Plasmin, substilisin-like endoproteases, tissue plasminogen activator, and urokinase plasminigen activator are involved in activation of latent TGF-beta(1) in human seminal plasma
51. Development and characterization of nontumorigenic and tumorigenic epithelial cell lines from rat dorso-lateral prostate
52. Effect of TGF-β1, TGF-α and EGF on cell proliferation and cell death in rat ventral prostatic epithelial cells in culture
53. Heparin-binding growth factor/prostatropin attenuates inhibition of rat prostate tumor epithelial cell growth by transforming growth factor type beta
54. Influence of transforming growth factor-beta I and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostate-derived fibroblasts
55. Interaction of epidermal growth factor and transforming growth factor β in human prostatic epithelial cells in culture
56. Transforming growth factor-β1 upregulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium
57. Stromal cells of the human prostate: Initial isolation and characterization
58. Induction of smooth muscle cell phenotypes in cultured human prostatic cells
59. The prostatic ductal system in rats: Regional variation in morphological and functional activities
60. Prostatic ductal system in rats: Tissue specific expression and regional variation in stromal distribution of transforming growth factor-β1
61. Changes in TGF-β localization in the rat prostatic ductal system during castration-induced regression
62. Transforming growth factor-β1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells
63. Prostate cancer cells lose their sensitivity to TGFb1 growth inhibition with tumor progression
64. Differential effects of transforming growth factor β on human prostate cancer cell lines in vitro
65. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement
66. Deletion of cells by apoptosis during castration-induced involution of the rat prostate
67. Activation of programmed cell death in the rat ventral prostate after castration
68. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
69. Expression and localization of transforming growth factor-β receptors type I and type II in the rat ventral prostate during regression
70. Expression of transforming growth factor-beta in the rat ventral prostate during castration induced programmed cell death
71. Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens
72. Early castration induced upregulation of transforming growth factor β1 and its receptors is associated with tumor apoptosis and a major decline in serum prostate specific antigen in prostate cancer patients
73. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors
74. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation
75. Estrogen induces apoptosis in a rat prostatic adenocarcinoma: Associations with an increased expression of TGF-β1 and its type-I and type-II receptors
76. Developmental and hormonal regulation of transforming growth factor-β1 (TGFβ1), -2, and -3 gene expression in isolated prostatic epithelial and stromal cells: Epidermal growth factor and TGFβ interactions
77. Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostates
78. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factorbeta1 on programmed cell death through a p53- and IGF-independent mechanism
79. Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-beta and retinoic acid in the human prostate adenocarcinoma cell line PC-3
80. Regulation of apoptosis induced by transforming growth factor-beta1 in nontumorigenic rat prostatic epithelial cell lines
81. Restoration of transforming growth factor β signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1 mediated apoptosis
82. Serum PSA after antiandrogen therapy
83. Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer
84. Alterations of transforming growth factor β1 (TGFβ1) and TGF-β receptor expression with progression in Dunning rat prostatic adenocarcinoma sublines
85. Elevated levels of circulating interleukin-6 and transforming growth factor β1 in patients with metastatic prostatic carcinoma
86. Potential role of T-lymphocytes in prostate tumor growth enhancement by transforming growth factor beta1 (TGFb1)
87. Modulation of transforming growth factor β1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix
88. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival
89. Transforming growth factor β1 expression in human colorectal tumours: An independent prognostic marker in a subgroup of poor prognosis patient
90. Transforming growth factorβ1: Comparative immunohistochemical localization in human primary and metastatic prostate cancer
91. Role of interleukin 19 and transforming growth factor β1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficient mice
92. Transforming growth factor β1 is a target for the von Hippel-Lindau Tumor suppressor and a critical growth factor for clear cell renal carcinoma
93. Blocking transforming growth factor β signaling in transgenic epidermis accelerates chemical carcinogenesis: A mechanism associated with increased angiogenesis
94. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment
95. Acceleration of human prostate cancer cell growth in vivo by factors produced by prostate and bone fibroblasts
96. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells
97. Osteoblasts synthesize and respond to transforming growth factor type b in vitro
98. Osteoblast conditioned media contain TGF-β1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components
99. Insensitivity to growth inhibition by TGF-β1 correlates with a lack of inhibition of the CDK2 activity in prostate cancer cells
100. Overexpression of transforming growth factor (TGF) β1 type II receptor restores TGFβ1 sensitivity and signaling in human prostate cancer cells
101. Loss of expression of transforming growth factor-β receptors is associated with poor prognosis in prostate cancer patients
102. Increased SMAD expression and activation are associated with apoptosis in normal and malignant prostate after castration
103. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
104. MAD-related genes in the human